<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03960840</url>
  </required_header>
  <id_info>
    <org_study_id>CYTB323A12101</org_study_id>
    <nct_id>NCT03960840</nct_id>
  </id_info>
  <brief_title>CD19-specific CAR-T Cells in CLL/SLL and DLBCL</brief_title>
  <official_title>Phase I, Open Label, Multicenter, Dose Escalation Study of CD19-specific CAR-T Cells in Adult Patients With CLL/SLL and DLBCL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first-in-human study to evaluate the feasibility, safety and preliminary antitumor
      efficacy of autologous T cells genetically engineered with a CD19-specific chimeric antigen
      receptor (CAR) and manufactured with a new process. CAR-T cells will be investigated in
      combination with ibrutinib in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma
      (SLL) and as single agent in diffuse large B-cell lymphoma (DLBCL).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 27, 2019</start_date>
  <completion_date type="Anticipated">March 27, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 27, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose recommendation: incidence and nature of Dose Limiting Toxicities (Dose Escalation part only)</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: incidence and severity of AEs and SAEs, including changes in laboratory values, ECG and vital signs</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability: ibrutinib dose modifications in the CLL/SLL arm</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Manufacture success: number of patients infused with planned target dose</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cellular kinetics: CAR transgene levels by quantitative polymerase chain reaction (qPCR) in peripheral blood, bone marrow and lymph nodes</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity: cellular and humoral responses to the CAR transgene</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response in CLL/SLL: CR/PR per iwCLL response criteria</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response in DLBCL: ORR/CR/PR per Lugano criteria</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) in CLL/SLL and DLBCL</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Diffuse Large B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>CLL/SLL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation and expansion of YTB323 in combination with ibrutinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DLBCL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation and expansion of YTB323 single agent in DLBCL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YTB323 and ibrutinib</intervention_name>
    <description>Single infusion of YTB323 and daily ibrutinib</description>
    <arm_group_label>CLL/SLL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YTB323 single agent</intervention_name>
    <description>Single infusion of YTB323</description>
    <arm_group_label>DLBCL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ECOG performance status 0-1

          -  CLL or SLL diagnosis according to iwCLL criteria

          -  CLL/SLL in SD or PR after at least 6 months of ibrutinib, either as second or
             subsequent line of therapy

          -  DLBCL diagnosis by local histopathology

          -  DLBCL relapsed or refractory after 2 or more lines of therapy, including autologous
             hematopoietic stem cell transplantation (HSCT)

        Exclusion Criteria:

          -  Prior CD19-directed therapy

          -  Prior administration of a genetically engineered cellular product

          -  Prior allogeneic HSCT

          -  Richter's transformation

          -  Active CNS lymphoma

          -  Targeted small molecule or kinase inhibitor within 2 weeks from leukapheresis

          -  Anti-CD20 monoclonal antibodies within 4 weeks prior to infusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Chicago Medical Center Hematology and Oncology</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elaine Hoekstra</last_name>
      <phone>773-834-8980</phone>
      <email>ehoekstra1@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Riedell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center SC - CTL019C2201</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Wesson</last_name>
      <phone>913-588-6029</phone>
      <email>wwesson@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Leyla Shune</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute Drug Ship - 4</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>615-329-7274</phone>
    </contact>
    <investigator>
      <last_name>Ian W. Flinn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin, Inc.</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Wall</last_name>
      <phone>414-805-4600</phone>
      <email>lwall@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Nirav Shah</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 21, 2019</study_first_submitted>
  <study_first_submitted_qc>May 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2019</study_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CD19 CAR-T cells, CLL, SLL, ibrutinib, DLBCL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

